Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26384531 | 0.84 | ADRB2 (0.49) | GAALOXL2ADRB2KDM4ECYP3A4 | |
| SCHEMBL17888393 | 0.79 | ALDH1A1 (0.43) | GAAPDE10AKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL12140714 | 0.79 | GAA (0.58) | GAAKDM4EMAPTTSHRSMN1; SMN2 | |
| SCHEMBL17886890 | 0.79 | HDAC1 (0.45) | GAAPDE10ATSHRSMN1; SMN2HDAC4 | |
| SCHEMBL12779730 | 0.78 | CD274 (0.45) | GAAPDE10ACD274TSHRSMN1; SMN2 | |
| Water SCHEMBL29067376 | 0.77 | L3MBTL1 (0.46) | GAAKDM4ETSHRSMN1; SMN2MEN1 | |
| SCHEMBL9580986 | 0.77 | LOXL2 (0.41) | GAALOXL2ADRB2KDM4ECYP3A4 | |
| SCHEMBL6345478 | 0.77 | CYP11B1 (0.42) | GAALOXL2ADRB2KDM4ECYP3A4 | |
| SCHEMBL7940302 | 0.77 | HCAR3 (0.44) | GAALOXL2ADRB2KDM4ECYP3A4 | |
| SCHEMBL7934995 | 0.77 | GABRP (0.48) | LOXL2ADRB2KDM4ECYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| WO-2023064585-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-3177612-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2022-02-23 | — | — | EP | disclosed |
| EP-3177611-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2021-10-06 | — | — | EP | disclosed |
| EP-3041841-B1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2019-06-05 | — | — | EP | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| EP-2064177-B1 | PROTEASE INHIBITORS | TAIMED BIOLOGICS INC (TW) | 2017-04-05 | — | — | EP | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-9085577-B2 | 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-07-21 | — | — | US | disclosed |
| CN-1027447-C | Insecticidal/acaricidal composition containing alpha-unsaturated amine | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-01-18 | — | — | CN | disclosed |
| CN-1093083-A | The method for preparing α-unsaturated amine or its salt | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-10-05 | — | — | CN | disclosed |
| CN-1091737-A | The method for preparing amine compound or its salt | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-09-07 | — | — | CN | disclosed |
| EP-0302389-B1 | Alpha-unsaturated amines, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1993-12-22 | — | — | EP | disclosed |
| US-5214152-A | Insecticides, miticides | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-05-25 | — | — | US | disclosed |
| EP-0529680-A2 | Intermediates, their production and their use for preparing alpha-unsaturated amines | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
| US-5175301-A | Insecticide, miticide, pesticide | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-12-29 | — | — | US | disclosed |
| EP-0509559-A2 | Alpha-unsaturated amines, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-21 | — | — | EP | disclosed |
| CN-1031079-A | Alpha-unsaturated amines, process for their production and their use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1989-02-15 | — | — | CN | disclosed |
| EP-0302389-A2 | Alpha-unsaturated amines, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | GAA 3271/4885PDE10A 902/4885LOXL2 1563/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | GAA 3271/4885PDE10A 902/4885LOXL2 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.